Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
NCT07481981 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
- Lead sponsor
- Insmed Incorporated
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 21, 2026
- Completion date
- January 28, 2029
- Enrollment
- 344 (estimated)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.